Pretargeted brain PET imaging reveals amyloid-β pathology using a TCO-modified antibody and a fluorine-18-labeled tetrazine.

ABSTRACT:

Background

Antibody-based positron emission tomography (PET) imaging holds great promise for visualizing disease-related proteins in the brain. However, its clinical utility is limited by poor antibody penetration across the blood-brain barrier (BBB) and the requirement for long-lived radionuclides due to slow antibody pharmacokinetics. Pretargeted imaging strategies, in which antibody administration and radioligand injection are separated in time, enable the use of short-lived, high-resolution PET-compatible radionuclides such as fluorine-18.

Methods

A bispecific antibody, Bapi-Fab8D3, which targets both amyloid beta (Aβ) and the transferrin receptor (TfR) for TfR-mediated transport across the BBB, was conjugated with trans-cyclooctene (TCO) to enable in vivo click chemistr

SUBMITTER: Lopes van den Broek S 

PROVIDER: S-EPMC12742193 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature